FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including an anti-HER2 antibody-drug conjugate (variants), a pharmaceutical composition for the treatment of HER2-expressing cancer, including the above-mentioned anti-HER2 antibody-drug conjugate, a method of treating HER2-expressing cancer, including the administration of an effective amount of anti- HER2 antibody-drug conjugate, and the use of an anti-HER2 antibody-drug conjugate in the production of a drug for the treatment of HER2-expressing cancer. In one embodiment, the anti-HER2 antibody-drug conjugate comprises a biparatopic antibody conjugated to an auristatin analog via a linker and with a low average drug to antibody ratio.
EFFECT: invention expands the arsenal of anti-HER2 agents.
36 cl, 18 dwg, 28 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIGEN-BINDING CONSTRUCTS AGAINST HER2 | 2014 |
|
RU2737882C2 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| CONJUGATES OF BINDER AND ACTIVE SUBSTANCE (ADC) HAVING ENZYMATICALLY CLEAVABLE GROUPS | 2017 |
|
RU2761390C2 |
| METHODS FOR PREPARING ANTIBODY-DRUG CONJUGATE COMPOSITIONS | 2015 |
|
RU2741470C2 |
| ANTIBODY-DRUG CONJUGATES BASED ON ERIBULIN AND APPLICATION METHODS | 2017 |
|
RU2754369C2 |
| METHODS OF USING BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 FOR TREATING BILE DUCT CANCER | 2019 |
|
RU2819802C2 |
| ANTIBODIES AGAINST EDB AND ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2758632C2 |
| PRODUCTION OF ANTIBODY-DRUG CONJUGATE AND ITS LYOPHILIZATION | 2018 |
|
RU2789476C2 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
